TF and neoplasm: Several studies have demonstrated prognostic value of mutation-based ctDNA-testing in patients with CRLM, primarily focussing on postoperative ctDNA in case of resectable liver metastases.41, 42, 43, 44 Importantly, the DELFI-TF fragmentome-based ctDNA detection method used in the current study is mutation-independent and tumour-type-independent, eliminating the need for tumour tissue profiling to obtain a view of the patient's tumour landscape.